Chris Fox

It’s back! Lymphoma Management 2026. Online and very reasonably priced. As ever a wonderful line up of speakers bringing up to date trial data and clinical insight to optimise the outcome of our patients. Looking forward to welcoming you to the course. lymphoma-action.org.uk/events/lymphom…

Excellent meeting & great 🇨🇿 group - thank you for the invitation and the Czech hospitality in beautiful Prague! @MarekTrnenyDr

Fascinating perspective & clear messages from @AmandaGoodall1 on the importance physician leadership. A 6 minute listen with @SocietyofHemOnc #SOHOinsider on the why, how & when!

@CwynKate @graham74GC @tobyeyre82 @SridharChaganti @drpramilak @bloodcancer_uk @CureLeukaemia #ProfTonyGoldstone #SirBruceKeogh

What a fabulous inaugural SOHO UK meeting in London. World class speakers across the blood cancer field integrated with fantastic speakers on leadership, a mentorship programme, industry and charity partners & much more… hats off to @charliecraddock @HT_Medical @SocietyofHemOnc

Optimising 1L intensive chemoimmunoRx in PCNSL… Impressive recruitment Ph3 RCT n=326 in a rare & challenging disease Congrats 👏🏾 to study teams in 🇬🇧 🇩🇪 🇮🇹 Now we wait for the data…. @GeraldIllerhaus @LizSchorb @CwynKate @FSchererMD @Jessica_Okosun @UoNPIBeacon @SU2CUK

On #WorldCancerDay, we’re proud to announce a major expansion of our partnership with Flutter Entertainment becoming our first ever global partner. Over the next three years, Flutter’s £3 million commitment will accelerate clinical trials by funding Cure Leukaemia Research Nurses across the UK. This is a continuation of their fundraising efforts, where colleagues have generated more than £2 million since 2023, improving access to potentially lifesaving treatments. Now, the partnership is scaling that impact globally, engaging 29,000 Flutter colleagues across 30+ countries through sport, endurance, and community fundraising. Read more about the partnership and what it will deliver here: cureleukaemia.co.uk/news/flutter-g… #DoMore #PositiveImpact

Your weekend listen, sorted 🎧 Have you tuned into Let’s Talk Blood Cancer, The Patients’ Podcast yet? Episodes 1-3 are now live on YouTube, Spotify, and all major podcast platforms. charitytoday.co.uk/cure-leukaemia…

📘𝘑𝘰𝘪𝘯 𝘶𝘴 𝘧𝘰𝘳 𝘵𝘩𝘦 𝘶𝘱𝘤𝘰𝘮𝘪𝘯𝘨 𝘐𝘈𝘊𝘏 𝘑𝘰𝘶𝘳𝘯𝘢𝘭 𝘊𝘭𝘶𝘣: 𝗧𝗮𝗳𝗮𝘀𝗶𝘁𝗮𝗺𝗮𝗯, 𝗹𝗲𝗻𝗮𝗹𝗶𝗱𝗼𝗺𝗶𝗱𝗲, 𝗮𝗻𝗱 𝗿𝗶𝘁𝘂𝘅𝗶𝗺𝗮𝗯 𝗶𝗻 𝗿𝗲𝗹𝗮𝗽𝘀𝗲𝗱 𝗼𝗿 𝗿𝗲𝗳𝗿𝗮𝗰𝘁𝗼𝗿𝘆 𝗳𝗼𝗹𝗹𝗶𝗰𝘂𝗹𝗮𝗿 𝗹𝘆𝗺𝗽𝗵𝗼𝗺𝗮 (𝗶𝗻𝗠𝗜𝗡𝗗): 𝗮 𝗴𝗹𝗼𝗯𝗮𝗹, 𝗽𝗵𝗮𝘀𝗲 𝟯, 𝗿𝗮𝗻𝗱𝗼𝗺𝗶𝘀𝗲𝗱 𝗰𝗼𝗻𝘁𝗿𝗼𝗹𝗹𝗲𝗱 𝘁𝗿𝗶𝗮𝗹 𝘸𝘪𝘵𝘩 𝘊𝘩𝘳𝘪𝘴 𝘍𝘰𝘹, 𝘓𝘢𝘶𝘳𝘪𝘦 𝘚𝘦𝘩𝘯 𝘢𝘯𝘥 𝘔𝘰𝘩𝘢𝘮𝘢𝘥 𝘔𝘰𝘩𝘵𝘺 🗓️ 𝘛𝘩𝘶𝘳𝘴𝘥𝘢𝘺, 𝘑𝘢𝘯 29, 2026 ⏰ 6𝘱𝘮 𝘊𝘌𝘛 🎟️ 𝘍𝘙𝘌𝘌 𝘳𝘦𝘨𝘪𝘴𝘵𝘳𝘢𝘵𝘪𝘰𝘯 𝘙𝘦𝘨𝘪𝘴𝘵𝘦𝘳 𝘯𝘰𝘸👉us06web.zoom.us/webinar/regist… @Mohty_EBMT @ProfChrisPFox @SehnLaurie

🎙️ EPISODE 3 — NOW LIVE! Professor @charliecraddock, Founder of Cure Leukaemia, answers the question, "Are we ever going to live in a world without blood cancer?" Search 'Let's Talk Blood Cancer' on Spotify, all major platform platforms, YouTube for the full episode or click here: youtu.be/fiMRDqiOxns

@DocHutchings Agree @DocHutchings …..but different design & populations…. This (larger) GenMab study was BsAb-mono & mainly 3L (starglo was majority 2L) & included HGBCL/DH/tFL whereas starglo was DLBCL only. Devil may be in the detail!

@ProfChrisPFox It is going to be interesting to see the data. Does not look like a home run. HR for PFS of 0.74 can be readily compared with the HR of STARGLO which is 0.41. And the OS HRs are 0.96 vs a significant 0.6.

Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) ir.genmab.com/news-releases/…

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma investor.incyte.com/news-releases/…

Krupka…Hodson et al 👏🏾 1 of 3 recent JCO papers with v similar conclusions re clinical utility of ctDNA in DLBCL This study unique: non-commercial assay & systematically dissects factors influencing assay performance Momentum towards clinical adoption. ascopubs.org/doi/10.1200/JC…

Hearing from patients on our #ClinicalTrials is a highlight for everyone at SCTU. For day 22 of our #AdventCalendar2025, meet Caroline, the first ever patient on our @SU2CUK-funded OptiMATe trial, for people with a rare form of #lymphoma Find out more - bit.ly/3KXPedZ

Did you see Caroline on the @SU2CUK live show on Friday? Caroline was the first participant on the SU2C-funded OptiMATe trial for people with a rare form of #lymphoma, led by @ProfChrisPFox @UniofNottingham and our team at SCTU. Find out more - bit.ly/3KXPedZ

Do come to what promises to be an excellent educational meeting across the haematological malignancy spectrum: the 1st SOHO UK Annual Meeting. Click here: sohouk.co.uk

Exciting news in UK lymphoma Glofit+GemOx approved for 2L use in #DLBCL in the UK by @NICEComms #lymsm bloodcancer.org.uk/news/new-treat…

The OptiMATe trial is for people with primary central nervous system #lymphoma (PCNSL). 📽️ Watch a video of Caroline and our SCTU team talking about this trial and what it means for patients 👇 youtu.be/XQ8iFv6TOKw